{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > MAPK > PD0325901CAS：391210-10-9
Molecular Formula：C16H14F3IN2O4
Molecular Weight：482.19
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 391210-10-9 |
| Name | PD0325901 |
| Molecular Formula | C16H14F3IN2O4 |
| Molecular Weight | 482.19 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 687-152-7 |
| MDL | MFCD08435926 |
| SMILES | O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO |
| Target Point | MEK |
| Passage | MAPK |
| Background | PD0325901 is a selective MEK inhibitor. |
| Biological Activity | PD0325901是选择性，可渗透细胞的 MEK 抑制剂， IC50为0.33 nM。[1-2] |
| IC50 | MEK1:0.33nM |
| Data Literature Source | [1]. Barrett SD，et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. [2]. Henderson YC，et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76. |
| Unit | Bottle |
| Specification | 10mg 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
